KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Change in Accured Expenses: 2012-2024

Historic Change in Accured Expenses for Xenon Pharmaceuticals (XENE) over the last 13 years, with Dec 2024 value amounting to $8.5 million.

  • Xenon Pharmaceuticals' Change in Accured Expenses rose 439.60% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year increase of 100.99%. This contributed to the annual value of $8.5 million for FY2024, which is 117.02% up from last year.
  • As of FY2024, Xenon Pharmaceuticals' Change in Accured Expenses stood at $8.5 million, which was up 117.02% from $3.9 million recorded in FY2023.
  • Over the past 5 years, Xenon Pharmaceuticals' Change in Accured Expenses peaked at $8.5 million during FY2024, and registered a low of $2.0 million during FY2020.
  • For the 3-year period, Xenon Pharmaceuticals' Change in Accured Expenses averaged around $6.8 million, with its median value being $8.1 million (2022).
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Change in Accured Expenses tumbled by 55.47% in 2020, and later soared by 171.36% in 2022.
  • Yearly analysis of 5 years shows Xenon Pharmaceuticals' Change in Accured Expenses stood at $2.0 million in 2020, then soared by 46.93% to $3.0 million in 2021, then skyrocketed by 171.36% to $8.1 million in 2022, then slumped by 51.24% to $3.9 million in 2023, then surged by 117.02% to $8.5 million in 2024.